NeuroCME
EXPERT INTERVIEWCME

Neuromyelitis Optica Spectrum Disorder: Improving Outcomes by Optimizing Choice of Therapy

Author(s)/Faculty: Patricia K. Coyle, MD, FAAN, FANA; Bruce A. C. Cree, PhD, MAS, FAAN, FANA; Benjamin M. Greenberg, MD, MHS, FANA, FAAN, CRND
Release Date: 3/31/2022Expiration Date: 3/30/2023
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system, mainly manifesting through recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis. Early stages of NMOSD are frequently misdiagnosed. The application of newer diagnostic criteria may facilitate earlier and more accurate diagnosis by assisting clinicians in identifying NMOSD in individuals who might have otherwise been diagnosed with other diseases. Treatment options have been limited until recently. Monoclonal antibodies have been used for patients with autoimmune disorders for several years, and their efficacy and safety in patients with NMOSD have been demonstrated. In this continuing education activity, expert clinicians review the latest updates on diagnosing and treating NMOSD.